Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 190 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hirschler B. Regulators flag possible birth defect link to GSK's HIV drug. Reuters Health News 2018:18 de mayo. [Ref.ID 102606]
2. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
4. Cita con resumen
Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, on behalf of the National Birth Defects Prevention Study. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. BMJ 2015;351:h3190. [Ref.ID 99250]
5. Cita con resumen
Anónimo. Baclofène et grossesse: malformations et syndromes de sevrage. Prescrire 2015;35:274-5. [Ref.ID 99127]
6.Tiene citas relacionadas Cita con resumen
Clarke R, Bennett D. Folate and prevention of neural tube defects. BMJ 2014;349:g4810. [Ref.ID 98164]
7. Cita con resumen
Pastemak B, Svanström H, Molgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 2013;310:1601-11. [Ref.ID 96391]
8. Cita con resumen
Anónimo. New weight-loss drugs and the US obesity epidemic. Lancet 2012;380:308. [Ref.ID 93509]
9.Tiene citas relacionadas Cita con resumen
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strenghts of the disproportionality analysis of identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8. [Ref.ID 91873]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg L, for the EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010;341:1261. [Ref.ID 89778]
12.Tiene citas relacionadas Cita con resumen
Nulman I. Carbamazepine in pregnancy. BMJ 2010;341:1229-30. [Ref.ID 89771]
13. Cita con resumen
Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medications use during pregnancy and risk of birth defects. National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009;163:978-85. [Ref.ID 86933]
14.Tiene citas relacionadas Cita con resumen
15.Tiene citas relacionadas
Gardiner HM, Fouron JC. Folic acid fortification and congenital heart disease. BMJ 2009;338:1221-2. [Ref.ID 85956]
17.Tiene citas relacionadas
U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation Statement. Ann Intern Med 2009;150:626-31. [Ref.ID 85876]
18. Cita con resumen
Martínez-Frías ML, Bermejo E, Pérez B, Desviat LR, Castro M, Leal F, Mansilla E, Martínez-Fernández ML, Rodríguez-Pinilla E, Rodríguez L, Ugarte M, y Grupo de Trabajo del Estudio Colaborativo Español de Malformaciones Congénitas (ECEMC). Análisis de las frecuencias de todas las combinaciones genotípicas de 4 polimorfismos de genes implicados en el ciclo del folato en la población española. Med Clin (Barc) 2008;131:81-8. [Ref.ID 83436]
19. Cita con resumen
Devine S, West SL, Andrews E, Tennis P, Eaton S, Thorp J, Olshan A. Valitation of neural tube defects in the full featured - General Practice Research Database. Pharmacoepidemiol Drug Saf 2008;17:434-44. [Ref.ID 82981]
20.
De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernández B, Lee NS, Niyonsenga T. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135-42. [Ref.ID 80552]
Seleccionar todas
 
 1 a 20 de 190 siguiente >>